CL2020003163A1 - Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidina-2,4-diona y sus sales - Google Patents

Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidina-2,4-diona y sus sales

Info

Publication number
CL2020003163A1
CL2020003163A1 CL2020003163A CL2020003163A CL2020003163A1 CL 2020003163 A1 CL2020003163 A1 CL 2020003163A1 CL 2020003163 A CL2020003163 A CL 2020003163A CL 2020003163 A CL2020003163 A CL 2020003163A CL 2020003163 A1 CL2020003163 A1 CL 2020003163A1
Authority
CL
Chile
Prior art keywords
disease
thiazolidine
dione
ethoxy
disorder
Prior art date
Application number
CL2020003163A
Other languages
English (en)
Inventor
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Lopez Estefania Traver
COLLAZO Ana Maria GARCÍA
De La Cruz Moreno Maria Angeles Pérez
Original Assignee
Minoryx Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L filed Critical Minoryx Therapeutics S L
Publication of CL2020003163A1 publication Critical patent/CL2020003163A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe un método para tratar o prevenir una enfermedad o trastorno seleccionado del grupo que consiste en un trastorno del sistema nervioso central, enfermedad del hígado graso no alcohólica, esteatohepatitis no alcohólica, un trastorno granulomatoso crónico, síndrome de ovario poliquístico, un carcinoma tiroideo, un trastorno autoinmune tiroideo, un adenoma hipofisiario, ateroesclerosis, hipertensión, una enfermedad a la piel, una inflamación y una enfermedad autoinmune, una enfermedad respiratoria inflamatoria y una enfermedad mitocondrial mediante la administración de 5-[[4-[2-[5-acetilpiridina-2- il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona o una sal del mismo a un sujeto que lo necesita. También se describe un 5-[[4-[2-[5- acetilpiridina-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona para su uso en una composición farmacéutica o en la elaboración de un medicamento para tratar o prevenir una enfermedad mitocondrial.
CL2020003163A 2018-06-06 2020-12-04 Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidina-2,4-diona y sus sales CL2020003163A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382402 2018-06-06

Publications (1)

Publication Number Publication Date
CL2020003163A1 true CL2020003163A1 (es) 2021-07-02

Family

ID=62716011

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003163A CL2020003163A1 (es) 2018-06-06 2020-12-04 Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidina-2,4-diona y sus sales

Country Status (14)

Country Link
US (2) US20210228558A1 (es)
EP (1) EP3801517A1 (es)
JP (1) JP7510170B2 (es)
KR (1) KR20210031867A (es)
CN (1) CN112823004A (es)
AU (1) AU2019283650A1 (es)
BR (1) BR112020024939A2 (es)
CA (1) CA3102584A1 (es)
CL (1) CL2020003163A1 (es)
EA (1) EA202092954A1 (es)
IL (1) IL279186A (es)
MX (1) MX2020013182A (es)
SG (1) SG11202012095XA (es)
WO (1) WO2019234690A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
EP3801515A1 (en) 2018-06-06 2021-04-14 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2131578T5 (es) 1992-04-30 2010-03-31 Institut Pasteur Deteccion rapida de resistencia a antibioticos en mycobacterium tuber culosis.
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
GB0510469D0 (en) * 2005-05-23 2005-06-29 Leuven K U Res & Dev Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
AU2012203941A1 (en) * 2006-06-27 2012-07-26 Sandoz Ag New method for salt preparation
EP2032521B1 (en) * 2006-06-27 2009-10-28 Sandoz AG New method for salt preparation
US20150224120A1 (en) * 2011-09-14 2015-08-13 Catherine Clelland Compositions and methods for treating hyperprolinemia-associated mental disorders
AU2014236510A1 (en) * 2013-03-14 2015-09-24 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
MX2016012687A (es) 2014-04-02 2017-04-27 Minoryx Therapeutics S L Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
DK3559010T3 (da) 2016-12-23 2022-08-15 Minoryx Therapeutics S L Fremgangsmåde til fremstilling af 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedion og salte deraf

Also Published As

Publication number Publication date
JP2021527061A (ja) 2021-10-11
IL279186A (en) 2021-01-31
JP7510170B2 (ja) 2024-07-03
BR112020024939A2 (pt) 2021-03-09
MX2020013182A (es) 2021-02-26
CN112823004A (zh) 2021-05-18
US20210228558A1 (en) 2021-07-29
WO2019234690A1 (en) 2019-12-12
AU2019283650A1 (en) 2021-01-07
US20240091210A1 (en) 2024-03-21
CA3102584A1 (en) 2019-12-12
KR20210031867A (ko) 2021-03-23
EA202092954A1 (ru) 2021-04-08
EP3801517A1 (en) 2021-04-14
SG11202012095XA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
CL2020003163A1 (es) Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidina-2,4-diona y sus sales
HRP20211032T1 (hr) Postupci za uporabu agonista fxr
CY1124116T1 (el) 5-[[4-[2-[5-(1-υδροξυαιθυλ)πυριδιν-2-υλ]αιθοξυ]φαινυλ]μεθυλ]-1,3-θειαζολιδινο-2,4-διονη για την θεραπεια της μη αλκοολικης λιπωδους νοσου του ηπατος
HRP20192299T1 (hr) Liječenje nafld i nash
AR106582A1 (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
JP2018523676A5 (es)
AR105493A1 (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
AR108317A1 (es) Composiciones que comprenden coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
MA41291A (fr) Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
RU2019100221A (ru) Составы на основе антитела к CD19
BR112018011154A2 (pt) dispersões sólidas compreendendo um estimulador de sgc
BR112018007947A2 (pt) uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash
MA39443A1 (fr) Nouvelle formulation de méloxicam
Kobayashi et al. Regulation mechanism of ABCA1 expression by statins in hepatocytes
EA201370162A1 (ru) Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты
EA201692469A1 (ru) Производное 2-ациламинотиазола или его соль
RU2017114596A (ru) Лечение жировой болезни печени с применением антагонистов глюкокортикоидных и минералокортикоидных рецепторов
MA54043A (fr) Cercueil notamment pour l'inhumation en pleine terre
EA201890362A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПОДАВЛЕНИЯ ОБРАЗОВАНИЯ кзкДНК ВИРУСА ГЕПАТИТА B
BR112015030171A2 (pt) composto, composição farmacêutica, método para prevenir ou tratar uma doença ou seus sintomas, uma afecção ou um distúrbio mediado parcial ou completamente por receptores nicotínicos de acetilcolina, uso de 4-(5-(4- clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol-3-il) benzenossulfonamida
MA54382A (fr) Utilisation d'un extrait de cocculus hirsutus pour le traitement de la dengue
HRP20211727T1 (hr) Liječenja nealkoholnog steatohepatitisa (nash)